Source: Annual Congress 2009 - Severe asthma and its treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, L. Macchia, P. Paggiaro, Italian Omalizumab Group (Rome, Bari, Pisa, Origgio/VA, Italy). Italian real-life experience of omalizumab. Eur Respir J 2009; 34: Suppl. 53, 1866

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of omalizumab in real-life practice in India Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Adherence to omalizumab: a “real-life” study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Safety of formoterol in children and adolescents: experience from asthma clinical trials Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Considerations of a real life pragmatic clinical trial in adolescent asthma Source: Eur Respir J, 58 (3) 2100461; 10.1183/13993003.00461-2021 Year: 2021 The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Use of Omalizumab in children in real clinical practice. Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Reductions in exacerbations with omalizumab in a real-world setting Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Inhaler technique assessments in a real-life cohort of mepolizumab-treated patients Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018